Related references
Note: Only part of the references are listed.A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma
Hansoo Kim et al.
JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE (2018)
The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions
Katalin Bognar et al.
JOURNAL OF HEALTH ECONOMICS (2017)
Questioning Our APHINITY for More
Kathy D. Miller
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
Alison M. Pease et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review
Alison M. Pease et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
PROMISE AND PLAUSIBILITY: HEALTH TECHNOLOGY ADOPTION DECISIONS WITH LIMITED EVIDENCE
Bruce Campbell et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2016)
INTERNATIONAL HEALTH CARE SYSTEMS Australian Health Care - The Challenge of Reform in a Fragmented System
Jane Hall
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals
Chul Kim et al.
JAMA INTERNAL MEDICINE (2015)
A national study of the processes and outcomes of paediatric formulary applications in Australia
Yashwant K. Sinha et al.
MEDICAL JOURNAL OF AUSTRALIA (2014)
The right drug, but from whose perspective? A framework for analysing the structure and activities of drug and therapeutics committees
Mikael Hoffmann
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
How hard can it be to include research evidence and evaluation in local health policy implementation? Results from a mixed methods study
Bridie Angela Evans et al.
IMPLEMENTATION SCIENCE (2013)
Surrogate Outcomes in Clinical Trials A Cautionary Tale
Staffan Svensson et al.
JAMA INTERNAL MEDICINE (2013)
The need for worldwide policy and action plans for rare diseases
John Forman et al.
ACTA PAEDIATRICA (2012)
COVERAGE WITH EVIDENCE DEVELOPMENT FOR PHARMACEUTICALS: A POLICY IN EVOLUTION?
Joel Lexchin
INTERNATIONAL JOURNAL OF HEALTH SERVICES (2011)
Coverage with evidence development: The Ontario experience
Leslie Levin et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2011)
Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study
Jeppe Lerche la Cour et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Resource allocation and health technology assessment in Australia: Views from the local level
Gisselle Gallego et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2009)
The history of health technology assessment in Australia
David Hailey
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2009)
Share Paper
